The endpoint was analyzed using Finkelstein-Schoenfeld method. The method combines all-cause mortality, cumulative frequency of CV-related hospitalizations, change from baseline in NT-proBNP and change from baseline in 6MWT in a hierarchical fashion. The method compares every participant with every other participant within strata, assigning a +1 to the "better" participant and a -1 to the "worse" participant and 0 if they are "tied". Participants who had heart transplantation or implantation of a cardiac mechanical assist device were handled in the same manner as death. 'Win' represents a participant doing better based on hierarchical comparison. The reported unit is the total percent of "wins" for each treatment group from performing such a hierarchical comparison across stratification factors in the study.

The mITT population includes subjects who meet the definition of ITT which includes all randomized subjects who received at least one dose of IMP and have at least one post baseline efficacy assessment as well as an additional requirement which is to have a baseline eGFR >= 30 mL/min/1.73 m^2 . Subjects in this population were analyzed according to their assigned randomized treatment.

6MWT measures the total distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed.

The mITT population includes subjects who meet the definition of ITT which includes all randomized subjects who received at least one dose of IMP and have at least one post baseline efficacy assessment as well as an additional requirement which is to have a baseline eGFR >= 30 mL/min/1.73 m^2 . Subjects in this population were analyzed according to their assigned randomized treatment.

KCCQ is a 23-item participant-completed questionnaire that assesses health status and health-related quality of life in participants with heart failure. Eight domain scores were calculated for the KCCQ: Physical limitation, Social limitation, Quality of life, Self-efficacy, Symptom stability, Symptom frequency, Symptom burden, and Total symptoms (calculated as the mean of Symptom frequency and Symptom burden scores). The summary score of Overall Summary (calculated as mean of Physical limitation, Social limitation, Total symptoms, and Quality of life scores) was calculated. Domain and summary scores were scaled to range from 0 (minimum) to 100 (maximum); higher scores represent better health status.

The mITT population includes subjects who meet the definition of ITT which includes all randomized subjects who received at least one dose of IMP and have at least one post baseline efficacy assessment as well as an additional requirement which is to have a baseline eGFR >= 30 mL/min/1.73 m^2 . Subjects in this population were analyzed according to their assigned randomized treatment.

Serum TTR (Prealbumin) is an in vivo biomarker of stabilization.

The mITT population includes subjects who meet the definition of ITT which includes all randomized subjects who received at least one dose of IMP and have at least one post baseline efficacy assessment as well as an additional requirement which is to have a baseline eGFR >= 30 mL/min/1.73 m^2 . Subjects in this population were analyzed according to their assigned randomized treatment.

Number of deaths due to any cause was analyzed. Participants who had heart transplantation or implantation of a CMAD were handled in the same manner as death.

The mITT population includes subjects who meet the definition of ITT which includes all randomized subjects who received at least one dose of IMP and have at least one post baseline efficacy assessment as well as an additional requirement which is to have a baseline eGFR >= 30 mL/min/1.73 m^2 . Subjects in this population were analyzed according to their assigned randomized treatment.